CamptothecinTopoisomerase I InhibitorsDNA Topoisomerases, Type IAntineoplastic Agents, PhytogenicTopotecanTopoisomerase InhibitorsCamptothecaDNA DamageAntineoplastic AgentsEnzyme InhibitorsTeniposideTopoisomerase II InhibitorsStructure-Activity RelationshipDrug Screening Assays, AntitumorOrganosilicon CompoundsTumor Cells, CulturedRubiaceaeApoptosisAphidicolinOrganic Chemistry PhenomenaMolecular StructureCell Line, TumorKineticsEtoposideDNAKB CellsDNA Topoisomerases, Type IIDrug ResistanceDose-Response Relationship, DrugDNA, SuperhelicalAmsacrineCell SurvivalLeukemia L1210Molecular Sequence DataDNA ReplicationDNA CleavageCell LineDNA RepairCell CycleDrug Resistance, NeoplasmLactonesIntercalating AgentsIridoid GlucosidesInhibitory Concentration 50Substrate SpecificityEllipticinesLeukemia P388Base SequenceChemistry, OrganicMutationProdrugsProtein BindingDNA, NeoplasmNeoplasmsAmino Acid SequenceModels, MolecularAlkaloidsSecondary MetabolismCricetinaeDrug SynergismCell DivisionTumor Suppressor Protein p53NaphthoquinonesPoly(ADP-ribose) PolymerasesHeLa CellsDiterpenesHL-60 CellsIndenesAffinity LabelsCells, CulturedStereoisomerismTime FactorsAcrylamidesS PhaseNucleic Acid Synthesis InhibitorsHT29 CellsLeishmania donovaniDNA FragmentationIridoidsDNA-Binding ProteinsMagnetic Resonance SpectroscopyDrug CarriersMice, NudeColonic NeoplasmsEnzyme ActivationNucleosidesChromatography, High Pressure LiquidCatalysisDoxorubicinPhosphorylationCathaOligonucleotidesDichlororibofuranosylbenzimidazoleCaspasesStaurosporineSaccharomyces cerevisiaeCricetulusMitoxantroneDrug Administration ScheduleFlavanones